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Abstract Systemic lupus erythematosus (SLE) is a mul-
tisystemic disease, caused by a variety of factors, which
lead to immunological abnormalities. Osteopontin (OPN)
is a pleiotropic protein, important in bone remodeling and
immune system signaling. OPN, produced by various cells,
including immune cells, plays a key role in regulating
T-helper 1/T-helper 2 balance, stimulating B lymphocytes
to produce antibodies, regulating macrophages, neutrophils
and inducing dendritic cells. OPN expression is influenced
by genetic polymorphisms of its promoter, hormones and
cytokines. Over expression of OPN has been associated
with the pathogenesis of immune-mediated diseases. OPN
has been implicated in the development of murine model of
lupus and in humans with SLE. In this review, I will
present current state of research on the role of OPN and
OPN gene polymorphisms in pathogenesis and clinical
course of SLE. A better understanding of the role of OPN
in SLE will contribute to more precise diagnosis and
treatment of the disease.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic multi-
systemic disease of autoimmune origin, characterized by
involvement of multiple organs (skin, lungs, heart, joints,
blood vessels, liver, kidneys, hematologic and nervous
systems). SLE is caused by environmental, hormonal and
genetic factors which lead to immunological abnormalities
(Kotzin 1996; Mills 1994). Deregulation of B and T lym-
phocytes activation leads to production of autoantibodies
and abnormalities in cytokine expression. Autoantibodies
[against double-stranded DNA (ds-DNA), SS-A (anti-Ro),
SS-B (anti-La), anti-Sm, anti-RNP] form complexes with
antigens, which are deposited in organs, cause inflamma-
tion and tissue damage (Giles and Boackle 2013; Lindop
et al. 2012; Marks and Tullus 2012; Rekvig et al. 2012).
Deregulation in cytokine expression followed by inflam-
matory processes is also a cause of tissue injury. It was
demonstrated that interleukin (IL)-6, B lymphocytes stim-
ulators, IL-17, IL-18 and interferon (IFN)-a have the
pathogenic role in SLE (Yap and Lai 2013).
Osteopontin (OPN), also known as early T lymphocyte
activation-1 or secreted phosphoprotein 1, is a member of
the small integrin-binding ligand N-linked glycoprotein
(SIBLING) family proteins (Fisher et al. 2001; Ramaiah
and Rittling 2008; Rangaswami et al. 2006). OPN for the
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first time was identified in 1986 as a major sialoprotein of
bone, linking bone cells and hydroxyapatite, the main
inorganic constituent of human bone tissue (Oldberg et al.
1986). OPN is produced by various cell types such as
immune cells: B cells and T cells, natural killer (NK)T cells,
NK cells, macrophages, neutrophils, dendritic cells (DCs),
bone cells (osteoblasts and osteocytes), breast epithelial
cells or neurons. OPN can be found in many organs such as
bone, lung, liver, brain, joints, adipose tissue and body
fluids: blood, urine, bile and semen (Denhardt and Noda
1998; Ramaiah and Rittling 2008; Uede 2011). OPN has
been found to be an effective biomarker for a number of
cancers (Afify et al. 2009; Ramaiah and Rittling 2008) and
immune-mediated diseases, including multiple sclerosis
(Carecchio and Comi 2011; Harris and Sadiq 2009; Muru-
gaiyan et al. 2008), SLE (Kariuki et al. 2009; Kariuki and
Niewold 2010; Murugaiyan et al. 2008; Zandman-Goddard
and Shoenfeld 2003), rheumatoid arthritis (Cantor 1995;
Gravallese 2003; Murugaiyan et al. 2008), atherosclerosis
(Cho et al. 2009; Scatena et al. 2007), cardiovascular dis-
ease (Singh et al. 2007), inflammatory bowel disease (Glas
et al. 2011; Mishima et al. 2007), asthma (Frenzel and
Weiss 2011; Konno et al. 2011) and liver diseases (Cao
et al. 2012; Ramaiah and Rittling 2008; Yilmaz 2012).
OPN Gene: Structure and Polymorphism
Human OPN gene is mapped on the long arm of chromo-
some 4 (4q21–4q25). It is composed of seven exons. The
first exon is untranslated. Exons 2–7 contain coding
sequences. OPN gene promoter includes several types of
regulatory sequences: the TATA box, GC box, reverse
CCAAT cassette and several transcription factor-binding
sequences: PEA3, E2A, AP1 and Ets (Sodek et al. 2000).
Moreover, it was shown that OPN gene expression is
affected by a number of cytokines (e.g., IL-1b, IL-6, tumor
necrosis factor (TNF)-a, IFN-c), hormones (vitamin D,
estrogen, angiotensin II, glucocorticoids), platelet-derived
growth factor and oxidized low-density lipoprotein (Den-
hardt and Noda 1998). In addition, the expression of OPN is
influenced by genetic polymorphisms of its promoter (Chiu
et al. 2010; Jiang et al. 2013). OPN gene is highly poly-
morphic. Several polymorphisms in the human OPN gene
have been identified: in the 50 flanking region, in exons and
introns and in the 30 untranslated region (Giacopelli et al.
2003; Iwasaki et al. 2001; Mochida et al. 2004).
Structure, Metabolism and Function of OPN
Osteopontin is a pleiotropic protein and its functions are
linked to various physiological functions and pathological
conditions. OPN interacts with cells via two binding
domains. Through the adhesive RGD motif (arginine–gly-
cine–aspartate domain), OPN interacts with avb1, avb3,
avb5, avb6, a8b1 and a5b1 integrins (Denda et al. 1998;
Hu et al. 1995; Yokosaki et al. 2005). Moreover, OPN
contains a SVVYGLR domain that mediates interactions
with a9b1, a4b1 and a4b7 integrins (Green et al. 2001; Ito
et al. 2009). OPN signaling via integrins modulates the
phosphorylation of kinases which are involved in NF-jB
activation and regulation of cytokines production (Urtasun
et al. 2012). Osteopontin contains an aspartate-rich region
near the C-terminal sequence. This domain is exposed as a
result of proteolysis by thrombin and is able to interact with
the CD44 receptors. It enables T cell chemotaxis and
fibroblast adhesion. CD44 ligation with OPN leads to
reduction in IL-10 gene expression in macrophages (Weber
et al. 1996).
Osteopontin function is highly modified by post-trans-
lational modifications, including phosphorylation, O-linked
glycosylation, sialylation and tyrosine sulfation. They are
necessary for OPN regulation of mineralization, bone
resorption and migration of cancer cells (Al-Shami et al.
2005; Gericke et al. 2005; Kazanecki et al. 2007; Razzouk
et al. 2002).
OPN, secreted by osteoblasts, osteoclasts and osteo-
cytes, is important in mineralization and bone resorption
(Denhardt and Guo 1993; Denhardt and Noda 1998).
Recently, this protein was found to be relevant in regula-
tion of immunity and inflammation, angiogenesis,
oncogenesis, cancer progression and apoptosis (Cantor
1995; Cao et al. 2012; Denhardt and Guo 1993; Murugai-
yan et al. 2008). Due to the fact that OPN is expressed by
many different cell types of the immune system, is up-
regulated in response to injury and inflammation and reg-
ulates immunological response, it may be classified as a
cytokine (Brown 2012; Denhardt and Guo 1993; Heilmann
et al. 2009; Koh et al. 2007; Wang and Denhardt 2008).
Osteopontin is highly expressed by macrophages and reg-
ulates their migration, activation, capacity for phagocytosis
and nitric oxide production (Ashkar et al. 2000; Brown
2012; Wang and Denhardt 2008; Weber et al. 1996). It has
been demonstrated that OPN is a chemoattractant for
neutrophils (Koh et al. 2007; Wang and Denhardt 2008)
and induces DCs maturation. OPN promotes activation of
T lymphocytes, and regulates the T-helper 1 (Th1)/Th2
balance. Via interaction with avb3 integrin, OPN up-reg-
ulates IL-12. Through CD44 receptor, OPN downregulates
IL-10 (Ashkar et al. 2000). Recent findings revealed that
non-secreted form of OPN enhances IFN-a expression
through the IFN regulatory factor 7 activation upon Toll-
like receptor (TLR)9 stimulation in plasmacytoid DCs
(pDC) (Shinohara et al. 2006). Moreover, OPN activates
and stimulates antibodies production by B lymphocytes
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(Ashkar et al. 2000; Iizuka et al. 1998; Lampe et al. 1991).
In addition, some studies suggested that OPN enhances IL-
17 producing Th17 cell responses by inhibiting the pro-
duction of IL-27 and IL-17 inhibitor produced by pDC
(Murugaiyan et al. 2008; Shinohara et al. 2008).
Role of OPN in SLE
Studies Performed in Murine Models of SLE
OPN was reported to be highly expressed in the MLR/lpr
mouse (commonly used model of the human SLE) (Iizuka
et al. 1998; Lampe et al. 1991; Miyazaki et al. 2005; Weber
and Cantor 2001; Wu¨thrich et al. 1998). In mice, CD4-/
CD8- T cells expressed high levels of OPN. Overexpres-
sion of OPN in murine model of SLE induces B cell
activation and IgG and IgM production, elevated autoan-
tibodies (including anti-ds-DNA) levels and enhanced
cytokine expression (TNF-a, IFN-c and IL-1b) (Iizuka
et al. 1998; Miyazaki et al. 2005; Weber and Cantor 2001;
Wu¨thrich et al. 1998). Overproduction of these cytokines
has been shown to be involved in the pathogenesis of SLE
(Yap and Lai 2013). The biological importance of OPN in
IFN-a responses was emphasized by the finding that in the
absence of OPN in mice, IFN-a production by pDC
through TLR9 pathway was impaired (Shinohara et al.
2006). Moreover, it has been found that elevated circulat-
ing levels of OPN are associated with renal damage in the
MLR/lpr mice (Miyazaki et al. 2005; Ophascharoensuk
et al. 1999; Wu¨thrich et al. 1998).
Studies Performed in Humans
In the literature, there are reports suggesting that OPN
participates in the pathogenesis of some autoimmune dis-
eases (Cantor 1995; Cho et al. 2009; Denhardt and Guo
1993; Gravallese 2003; Murugaiyan et al. 2008; Ramaiah
and Rittling 2008; Scatena et al. 2007; Sodek et al. 2000;
Uede 2011).
In 1989, first report was published to connect OPN to
immunity (Patarca et al. 1989). In 1995, Katagiri and
colleagues for the first time evaluated whether elevated
OPN level can be detected in patients with autoimmune
diseases (Katagiri et al. 1995). These authors observed that
serum OPN level is elevated in SLE and RA patients
compared with healthy donors. Moreover, they described
two forms of OPN: large (64,000 Da) and small
(32,000 Da). The small form of OPN may be derived from
the large since it can be cleaved by thrombin. This
thrombin-cleaved OPN exposes an epitope for integrin
receptors: a4b1, a9b1 and a9b4 (Green et al. 2001; Ito
et al. 2009). Li et al. (1999) and Lou et al. (2006) likewise
demonstrated that plasma OPN concentration is elevated in
SLE patients. In another study, Wong et al. (2005) mea-
sured the plasma concentration of OPN in 54 Chinese SLE
patients with (renal disease in SLE: RSLE) and without
(SLE) renal impairment. They demonstrated that OPN
concentrations were significantly higher in SLE and RSLE
patients than in controls (p \ 0.001) and correlated posi-
tively and significantly with SLE disease activity index
(SLEDAI) (r = 0.308, p = 0.023; Wong et al. 2005).
Moreover, in RSLE patients, OPN concentration showed a
positive correlation with the pro-inflammatory cytokine IL-
18 level (r = 0.404, p = 0.037). This cytokine exerts a
variety of effects on DCs, T lymphocytes and NK cells, and
is an inducer of IFN-a to promote Th1 differentiation (Yap
and Lai 2013). Wong et al. (2005) suggested that in com-
bination with the inflammatory activities of IL-18, OPN
can enhance the Th1-mediated inflammatory process in the
exacerbation of SLE and RSLE. Similar finding was
observed by Afify et al. (2009) in children with SLE (40
patients and 30 matched controls). The study showed that
OPN concentrations were significantly higher in SLE
patients with and without renal disease than in the controls
(p = 0.000 and p = 0.002, respectively). Moreover,
plasma OPN level correlated positively with disease
activity index in both groups (r = 0.34, p = 0.04). In
patients with renal disease, there was a positive correlation
between IL-18 and OPN concentration (r = 0.48,
p = 0.004). Rullo et al. (2013) hypothesized that increased
circulating plasma OPN levels may be associated with
organ damage in pediatric SLE (n = 42) and adult SLE
(n = 23). Plasma OPN concentrations were significantly
higher in both groups than in controls (p = 0.03 and
p = 0.02, respectively). In addition, Rullo et al. (2013)
showed that increased OPN is associated with higher titer
of antibodies to ds-DNA (p = 0.001) and elevated IFN-a
(p = 0.02), which were shown to be important in patho-
genesis and clinical manifestations of SLE (Bengtsson
et al. 2000). Moreover, Rullo et al. (2013) showed a
positive correlation between OPN and SLEDAI in six
months.
These results (summarized in Table 1) suggest that the
production of OPN is associated with SLE development
and may serve as a potential marker of SLE activity and
organ damage.
Role of OPN Gene Polymorphism in SLE
Studies Performed in Murine Models of SLE
Polymorphic OPN alleles have been implicated in the
mouse model of lupus in the study of Miyazaki et al.
(2005). These authors reported that OPN gene
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polymorphism induces enhanced expression of immuno-
globulins: IgG3, Ig2a and IgM and cytokines: IFN-c, TNF-
a, IL-1b which play an important role in lupus mice
models and in human SLE. It was shown that type I IFN
signaling pathway is essential for up-regulation of TLR7
and TLR9 receptors in B lymphocytes and activation of B
lymphocytes through these receptors to produce lupus-
specific autoantibodies (Thibault et al. 2008). The role of
TNF-a in lupus mice models is controversial. In some
mouse models, the deficiency of TNF-a provoked auto-
immunity (Kontoyiannis and Kollias 2000). In contrast,
TNF-a concentration was elevated in sera and renal tissue
of MLR/lpr lupus mice and the levels of this cytokine
correlated with the severity of kidney disease (Yokoyama
et al. 1995). Overproduction of IL-1b has been shown to be
involved in the pathogenesis of SLE. Mice deficient in IL-
1b developed lower levels of anti-ds-DNA antibodies
(Voronov et al. 2006).
Studies Performed in Humans
A number of studies demonstrated that increased plasma
concentration, as a result of OPN gene polymorphism and
increased protein expression, was associated with SLE
susceptibility and/or clinical manifestations of the disease
in humans. Study of Forton et al. (2002), including 81
Caucasoid SLE patients and Caucasoid 79 controls,
showed that polymorphic T allele of the silent poly-
morphism 707 C[T (rs1126616) is associated with
opportunistic infections and renal insufficiency (p = 0.0598
and p = 0.0431, respectively) but is protective for avas-
cular necrosis (p = 0.0382). There was no association with
cutaneous lupus, gastrointestinal lupus and specific labo-
ratory features (Forton et al. 2002). This was the first
demonstration of a phenotypic association with an OPN
gene polymorphism but the authors admitted that the
number of patients participating in the study was too low. In
a study of 394 Italian SLE patients and 479 matched con-
trols, a total of 13 single nucleotide polymorphisms (SNPs)
in OPN gene were identified (six in the 50 flanking region,
one in intron 3, three in exons 6, 7 and 3 in the 30-UTR;
Table 2) (D’Alfonso et al. 2005). Five of these SNPs
were newly identified. Two polymorphisms: -156G[GG
(rs7687316) and ?1239A[C (rs9138) were significantly
associated with SLE. The -156G and ?1239C alleles were
more frequent in SLE patients than in the control group
(p = 0.006 and p = 0.00094, respectively). In addition,
significant association was seen between lymphadenopathy
and -156 genotypes (p = 0.0011). Significantly increased
OPN serum level was detected in healthy individuals car-
rying ?1239C (p = 0.002). The authors suggested that
-156G[GG and -1239A[C polymorphisms predispose to
high production of OPN and susceptibility to SLE.
These data suggest that OPN genetic variants have a key
role in creating a background favoring lymphocyte accu-
mulation and leading to the development of autoimmunity.
OPN may exert its effect through its capacity to stimulate
proliferation and to inhibit apoptosis of lymphocytes or
Table 1 Main studies about osteopontin (OPN) role in human SLE




10 SLE patients Serum OPN level were elevated
in SLE patients but not in
healthy donors
Two forms of OPN: large and
small were detected. The small
form may be derived from the





54 SLE patients Plasma OPN concentrations were
significantly increased in SLE
and RSLE patients (p \ 0.001)
and the elevation correlated
positively with SLEDAI
(r = 0.308, p = 0.023)
In RSLE patients, OPN
concentration showed a
positive correlation with IL-18
level (r = 0.404, p = 0.037)
Lou et al.
(2006)
38 SLE patients Plasma OPN concentrations were
significantly higher in SLE
patients than in controls
(p \ 0.001) and showed a
significant positive correlation




40 pSLE patients Plasma OPN concentrations were
significantly higher in SLE and
RSLE patients than in controls
(p = 0.002 and p = 0.000)
and correlated positively with
SLEDAI (r = 0.34, p = 0.04)
In patients with renal disease,
there was a positive correlation
between IL-18 and OPN




42 pSLE patients and
23 SLE adult
patients
Plasma OPN concentrations were
significantly higher in pSLE
and adult SLE patients than in
controls (p = 0.03 and
p = 0.02) and the elevation
correlated positively with six-
month SLEDAI in both groups
(r = 0.51 and 0.51, p = 0.001
and p = 0.01)
Increased OPN at baseline was
associated with antibodies to
ds-DNA (p = 0.001) and
elevated IFN-a (p = 0.02)
OPN osteopontin, SLE systemic lupus erythematosus, pSLE pediatric
SLE, RSLE renal disease in SLE, SLEDAI SLE disease activity index
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through its capacity to modulate the immune response by
inducing Th1 responses and potentiating polyclonal acti-
vation of B cells.
Xu et al. (2007a) demonstrated that single nucleotide
polymorphism at position 9259 in exon 7 of the OPN gene
(OPN gene 9250C[T) exists in the Chinese Han ethnic
population and is associated with SLE. The frequency of
TT genotype was significantly lower in SLE patients
(n = 158) than in the controls (n = 180; p = 0.001). The
frequency of TC genotype was significantly higher in
patients compared to controls (p = 0.088). When the SLE
patients and controls were separated into women and men,
significant differences of frequencies were noted in TT
genotype, TC genotype and allele in women, but not in
men (Xu et al. 2007a). Moreover, this polymorphism
appears to be associated with the susceptibility to lupus
nephritis in this population. The TT genotype was lower in
SLE patients with lupus nephritis (p \ 0.05) (Xu et al.
2007b). In a large study of 1,141 SLE patients (707
European-American, 434 African-American) Han et al.
(2008) performed the population-based case–control anal-
yses. It was reported that minor alleles of rs1126616 and
rs9138 (T and C, respectively) were significantly correlated
with higher risk of SLE in combined two ethnic groups of
males (p = 0.0005; OR 1.73, 95 % CI 1.28–2.33) but not
in females (Han et al. 2008). Moreover, significant gender–
gender interactions in rs1126616 and rs9138 were detected
(p = 0.001 and p = 0.0006, respectively). Furthermore,
haplotype analysis identified rs1126616T-rs1126772A-
rs9138C which demonstrated association with SLE in
general (p = 0.02; OR 1.30, 95 % CI 1.08–1.57), espe-
cially in males. Han et al. (2008) suggested that OPN gene
polymorphism is associated with SLE, especially in males
and it was the first description of a gender-specific human
lupus genetic association. In another study, Trivedi et al.
(2011) examined 246 patients diagnosed with SLE, geno-
typing the rs11730582, rs28357094, rs6532040 and rs9138
SNPs in the OPN gene. They proved that photosensitivity
in SLE patients was associated with the risk allele rs9138C
(p = 0.001; OR 3.245, 95 % CI 1.609–6.542). It is known
that cutaneous lupus is characterized by photosensitivity,
UV-mediated apoptosis of keratinocytes and an inflam-
matory infiltration into the skin. The accumulation of pDC
(IFN-a-producing cells) in the skin was demonstrated to be
important in these conditions (Blomberg et al. 2001). In
addition, the study of Trivedi et al. (2011) demonstrated
that the C allele of rs11730582 polymorphism is associated
with thrombocytopenia (p = 0.023; OR 2.12, 95 % CI
1.11–4.04) and hemolytic anemia (p = 0.036; OR 2.55,
95 % CI 1.06–6.13). Previous study of Kariuki et al. (2009)
revealed an association of the rs9138C allele with higher
levels of OPN and IFN-a in a small cohort of male SLE
patients (p = 0.0062 and p = 0.0087, respectively). The
mechanism by which OPN gene polymorphism modulates
serum IFN-a is unclear but murine data suggest a role of
OPN in IFN-a production by pDC (Shinohara et al. 2006).
Moreover, in African-American SLE subjects (n = 434),
participating in the study of Kariuki et al. (2009), two
SNPs: rs11730582 and rs28357094, were associated with
anti-ribonucleoprotein (anti-RNP) autoantibodies
(p = 0.0038; OR 2.9, 95 % CI 1.4–6.1 and p = 0.021; OR
3.9, 95 % CI 1.1–11.8, respectively).
Concluding Remarks
This review has summarized the advances in understanding
of the role of OPN in pathogenesis and outcome of SLE.
Osteopontin, a pleiotropic protein highly expressed by
various cell types such as cells of the immune system,
regulates immune response. A large number of publications
suggest that OPN participates in the pathogenesis of many
autoimmune diseases, including SLE. It has been demon-
strated that OPN expression is increased in SLE patients
and is associated with some clinical manifestations and
levels of activity, but with divergences in the different
populations studied. Causes of these differences include
probably ethnic and environmental factors (diet, medica-
tions, tobacco smoking, ultraviolet light) and still unknown
factors. The association of SLE and OPN gene polymor-
phism is still rarely reported. However, most of the results
indicate that it might be a good molecular marker for the
susceptibility to, and severity of SLE. Further studies
should improve our understanding of the disease and will
contribute to more precise diagnosis and treatment of SLE.
Current Challenges and Future Research Directions
There are reports suggesting the role of OPN and OPN
gene polymorphism in pathogenesis and/or clinical mani-
festations of SLE. Unfortunately, many of these studies do
not meet the current rigorous standards for non-biased
large-cohort trials. Future research should focus on
selecting the best study group to investigate the role of
OPN in SLE. Statistical analysis of the results should take
into account many factors, including sex, age, ethnic group,
diet, medications and environmental factors. Studies of
OPN gene polymorphism must take into account the gene–
gene, gene–environment interactions and ethnic factors.
Currently, little work has been focused on understanding
the molecular mechanism whereby OPN exerts its various
effects. Moreover, both randomized trials and long-term
follow-up studies are needed to show the efficacy of
treatment of autoimmune diseases (e.g., SLE) with anti-
OPN antibodies.
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